Treatment of esophageal cancer with radiation therapy: a pan-Chinese survey of radiation oncologists

Yun Zhang1,2,*, Jing Liu3,*, Wencheng Zhang4, Weiye Deng5,6, Jinbo Yue2

1 School of Medicine and Life Sciences, University of Jinan Shandong Academy of Medical Sciences, Jinan, Shandong, China
2 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China
3 Graduate Education Center, Shandong Academy of Medical Sciences, Jinan, Shandong, China
4 Tianjin Cancer Hospital, Tianjin, China
5 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6 Division of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas School of Public Health at Houston, Houston, Texas, USA

* These authors have contributed equally to this work

Correspondence to: Jinbo Yue, email: yuejinbo@hotmail.com

Keywords: esophageal cancer, radiation therapy, radiation oncologist, questionnaire

ABSTRACT

Lots of controversies were found about the treatment in relation to radiation therapy (RT) for esophageal squamous cell carcinoma (ESCC). We designed a questionnaire of these controversies to do a pan-Chinese survey of radiation oncologists (ROs). For operable ESCC, 53% ROs chose surgery plus postoperative chemoradiotherapy (CRT), while 40% chose preoperative CRT plus surgery. For target volume of postoperative RT, most ROs (92%) would delineate tumor bed plus involved lymph nodes region before surgery. For definitive RT, most ROs (81%) would give patients higher RT dose to 60–65 Gy. For radiation target volume, most ROs would give patients prophylactic irradiation of the bilateral superclavicular-lymph nodes region for cervical ESCC (93%), and the left gastric lymph nodes region for lower thoracic ESCC (72%). For the treatment of mediastinal lymph nodes, 72% ROs preferred elective nodal irradiation, while 28% did the involved nodal irradiation. For concurrent chemotherapy regimen, PF (5-Fu + cisplatin) and TP (cisplatin + paclitaxel) were used widely (49% and 46%, respectively). During simulation, four-dimensional computer tomography (4D CT) was not widely used (48%), even for cervical or lower thoracic ESCC (52%). For daily RT delivery, only 66% ROs would perform imaging guidance RT daily. In summary, more controversies existed in the treatment of ESCC with RT in China, including treatment strategy, radiation dose and target contour. Future goals include standardization of treatment strategy, radiation dose, and target contour, and application of 4D CT and daily imaging guidance, and pursuit of randomized trials in Chinese population.

INTRODUCTION

Esophageal cancer is the eighth most common cancer and the sixth leading cause of cancer-related mortality in the world [1]. Esophageal cancer has a higher incidence in China than in any other country [2, 3]. The incidence of esophageal cancer was 21.17 per 100000 [3], with the crude mortality rate was 15.58 per 100000, ranking the fourth leading cause of overall cancer deaths in 2012 in China [4]. Radiation therapy (RT) plays an important role in the comprehensive treatment of esophageal cancer [5]. Preoperative chemoradiotherapy (CRT) plus operation has been established as the standard of care for operable patients with esophageal cancer [6], as well as definitive CRT for inoperable patients [7], with high level evidence to improve local control and overall survival (OS) [6, 8]. Although the role of RT is established in the management of esophageal cancer, many controversies
exist on the treatment strategy and optimal radiation dose, as a result of the big differences on epidemiology, histology and tumor location for esophageal cancer between different countries [9]. For those reasons, the clinical management of esophageal squamous cell carcinoma (ESCC) including treatment strategy, may be highly variable across different countries and sometimes is likely guided by clinician experiences, even without high level evidence [9, 10]. Involved nodal irradiation (INI) or elective nodal irradiation (ENI) has been hotly debated in recent years [11]. For four-dimensional computer tomography (4D CT), although it is widely used in the simulation for lung cancer [12], how does it extend to esophageal cancer remains unknown in China.

As the highest prevalence country, it’s interesting to know how Chinese radiation oncologists (ROs) treat ESCC in daily practice. We aim to perform a national survey of clinical practice among Chinese ROs who treat ESCC. Through the survey, we anticipate finding the controversies on the treatment choice for ESCC, which may promote consensus on the treatment for ESCC in the future as well as trigger ROs’ interests to initiate prospective randomized clinical trials in China.

RESULTS

Demographics

A total of 380 ROs, from 27 provinces in China, answered the questionnaire (the survey response rate, 76%). ROs distributed evenly in 27 provinces in China (median, range: 15, 8–26) and 90% ROs came from the first class tertiary hospital. The age and experience of the respondents varied, with 75% ROs more than 40 years old and 59% having treated esophageal cancer more than 10 years. Targeted responses from 224 ROs, older than 40 years and more than ten years experiences in treating esophageal cancer, were finally analyzed.

Treatment strategy

91% ROs would select challenging cases for multi-disciplinary teamwork (MDT), 7% would discuss all cases, and only 2% never discussed. For operable, locally advanced ESCC, more than half would use surgery plus postoperative CRT rather than preoperative CRT plus surgery (Figure 1). 95% ROs recommended postoperative RT after surgery for locally advanced ESCC. For the reason not using preoperative trimodality, 57% ROs thought the preoperative RT would increase the risk of postoperative complications, such as bleeding, anastomotic leakage and healing delay, although 69% ROs knew the CROSS clinical trial. For the concurrent chemotherapy regimen, 5-Fu plus cisplatin (49%) and weekly paclitaxel plus cisplatin (46%) were commonly used, while the CROSS trial regimen, weekly paclitaxel and carboplatin was not most common (34%).

Simulation

Although 4D CT was available in 89% institutions, 48% ROs, whose institutions have 4D CT, would never use it in routine simulation for esophageal cancer. Only 52% ROs would use 4D CT simulation for cervical or lower thoracic ESCC. In addition to, routine CT simulation, 71% ROs used X-Ray barium fluoroscopy simulation to double check the localization of esophageal tumor. Besides CT, X-Ray barium and endoscopy (55% ROs), positron emission tomography (PET) (53%) or endoscopic mucosal clips (placing at the proximal and distal margins of the tumor, 20%) was used to facilitate tumor contour. After esophagectomy, most ROs would cover tumor bed plus involved lymph node regions before surgery (Figure 2).

Prescription doses

For inoperable, locally advanced thoracic ESCC, majority of ROs preferred to 60–65Gy rather than 50.4Gy, and minority would perform higher dose to 65–70Gy (Figure 3). The possible reasons why not use 50.4Gy were listed as follows: 51% ROs thought the dose was inadequate according to their experiences; 91% ROs thought there were many differences between Asian and Western countries, including epidemiology, etiology, pathology, and tumor position; 25% ROs thought the recurrence mainly happened in the GTV (gross tumor volume); Some ROs thought the INT-0123 trial used old technical (71%) and bigger margin than that of current clinical practice (75%).

Target volumes

The clinical target volume (CTV) would be defined as the primary tumor plus 3 cm (75% ROs), 4cm (16%), or 5 cm (9%) expansion superiorly and inferiorly along the length of the esophagus. However, for cervical cancer, only 40% ROs would prefer 3–5 cm expansion superiorly even beyond the upper anatomy bound of esophagus, cricoid cartilage; 32% ROs would define CTV not higher than cricoid cartilage, considering the radiation toxicity of hypopharynx or larynx; 28% ROs would use laryngoscopy to rule out skip esophagus metastasis into hypopharynx or higher, if not, then only expand CTV to cricoid cartilage.

For nodal CTV, the supraclavicular nodes regions were electively treated in patients for cervical (93%) and upper-thoracic (72%) lesions. For lesions of the distal esophagus, the left gastric regions were electively covered for majority of ROs (72%). The left gastric regions would include right cardinal nodes (73% ROs), left cardinal nodes (64%), nodes along the lesser curvature (67%), nodes...
along the greater curvature (13%), suprapyloric nodes (9%), infrapyloric nodes (6%), nodes along left gastric artery (49%), nodes along the common hepatic artery (12%), nodes along the celiac axis (20%), nodes at the splenic hilus and artery (4%).

For the mediastinal nodal CTV (Figure 4), most ROs would prefer ENI, rather than INI. Giving the definitive concurrent CRT, 80% ROs would shrink field during the RT course; the tumor CTV would be coned down to primary tumor plus 1 cm (46% ROs), or 2 cm (34%), or to primary tumor (20%). For organ at risk (OAR), most ROs would outline normal lungs, heart, spinal cord (65%) and normal esophagus (30%); minority would not outline brachial plexus (5%).

Planning evaluation and RT delivery

68% ROs thought it is not reasonable to use normal tissue dose-volume constraints of non-small cell lung cancer to evaluate OAR for esophageal cancer. During RT, skin tattoo without imaging guided was seldom used to set up patients (13%). Two-dimensional (2D) kilovoltage (kV) orthogonal imaging or electronic portal imaging device (EPID) daily (13%), three-dimensional (3D) kilovoltage (kV) cone-beam computer tomography (CBCT) or megavoltage (MV) CT imaging for Tomotherapy weekly (53%), were used for imaging guided radiotherapy (IGRT).

DISCUSSION

Results of this pan-Chinese survey of ROs indicated that variation of practice occurs in the treatment of ESCC in China, including treatment strategy, simulation, radiation dose, target contour and RT delivery. Trimodality is one of main treatment strategy for locally advanced ESCC. It’s difficult to decide the optimal treatment strategy between neoadjuvant CRT or adjuvant CRT in addition to surgery. There are also active controversies surrounding the dose and the principle of mediastinal lymph nodes irradiation. 4D CT and daily imaging guided RT are necessary to be performed to improve RT accuracy. Future goals include better classification of esophageal cancer, continued pursuit of randomized trials in Chinese population, standardization of treatment strategy, radiation dose, and target contour.

Trimodality strategy of neoadjuvant CRT and surgery have been established as the standard care for locally advanced esophageal cancer [6, 9, 13–15]. However, even majority of ROs (69%) knew the role of the CROSS trial, more than half of ROs chose surgery plus postoperative CRT rather than preoperative CRT plus surgery. What they (57% ROs) concerned is that neoadjuvant CRT may increase the risk of postoperative complications, such as bleeding, anastomotic leakage and healing delay, although CROSS trial has demonstrated that trimodality is associated with similar adverse-event rates compared with surgery alone [15]. The underlying reason is that Chinese ROs believed there is a big difference in treatment strategy between Eastern and Western patients with esophageal cancer, in addition to the clear difference in epidemiology, tumor biology [1]. A new study published in the Nature journal suggested that ESCC is a disease which is completely different from esophageal adenocarcinoma in its molecular characteristics [16], which may change the treatment of ESCC. Current Clinical Practice Guidelines in Oncology (NCCN Guideline) for esophageal cancer are primarily based on the research on Western population. Thus, trimodality may be not suitable for Chinese population [17].

![Figure 1: The treatment strategy for operable, locally advanced esophageal squamous cell carcinoma (ESCC).](image-url)
In fact, 23% patients with squamous cell carcinoma were recruited in the CROSS clinical trial and benefited more than those with adenocarcinoma in overall survival (OS) [6]. Besides, the choice might be influenced by the results of a prospective randomized study carried out by Xiao et al. [18], which showed adjuvant radiotherapy could prolong OS. However, a prospective phase III clinical trial from China (NCT01216527), which compared neo-adjuvant CRT followed by surgery for ESCC, had showed promising results that neo-adjuvant CRT improved survival among patients with locally advanced ESCC [19]. The results might change clinical practice for operable ESCC in China in the future. For concurrent chemotherapy regimen, preference was that cisplatin combined 5-Fu or paclitaxel, because Chinese oncologists embraced that cisplatin has more therapeutic efficacy than carboplatin [20]. Besides, part of ROs would choose weekly paclitaxel and cisplatin plus cetuximab, which was based on the

Figure 2: The target volume if giving postoperative radiotherapy for esophageal squamous cell carcinoma (ESCC).

Figure 3: The preferred definitive radiotherapy dose for non-operable, thoracic esophageal squamous cell carcinoma (ESCC).
EXEL clinical trial (NCT00815308) in China; this trial showed that cetuximab can be safely administered with CRT to patients with locally-advanced ESCC and may improve clinical response rate [21], although RTOG 0436 showed negative results for cetuximab concurrent with RT in esophageal cancer [22].

For non-operative ESCC, RTOG 8501 and INT 0123 clinical trial established definitive CRT using the RT dose of 50.4 Gy as the standard of treatment [23, 24]. Recently, a retrospective report based on 6584 patients also has confirmed that dose escalation does not improve OS [23]. However, the optimal RT dose is still hotly debated [9] after the publication of the randomized controlled trial INT-0123 [25], in that 50.4 Gy was used in the North America guideline [26] based on INT-0123 whereas 50–60 Gy was acceptable in the European guideline [27], more than 60 Gy was often used in China and Japan [28–30]. Most Chinese ROs preferred higher dose ≥ 60 Gy in clinical practice in our survey. Although INT-0123 is the only high level based study related with RT dose escalation [31], a recent review paper still commented “A further dose escalation should be considered as justified” [32]. Radiation dose escalation is a topic of clinical investigation in the setting of esophageal cancer for many years in an attempt to improve outcomes. Chen et al. constructed a propensity score matched study [high dose (60 Gy) vs standard dose (50–50.4 Gy)] based on 648 patients from Taiwan and found that higher dose may lead to better survival for non-operative localized ESCC patients undergoing concurrent chemoradiation (CCRT) [33]. A phase III clinical trial of cancer (NCT01937208) from China is ongoing to compare high dose (60 Gy) versus low dose (50 Gy) concurrent with chemotherapy using modern radiotherapy for inoperable ESCC [33]. Meanwhile, in most cases, local failure after combined CRT with a radiation dose of 50.4 Gy for inoperable esophageal cancer develops in the gross tumor volume [30]. A phase I/II clinical trial from M.D.Anderscon cancer center used a simultaneous integrated boost dose of 58.8–63 Gy to the gross tumor volume (GTV) concurrent with chemotherapy and showed promising local control [34]. Another dose escalation trial (NCT01843049) from China is ongoing to boost radiation dose within the primary tumor under the guidance of functional imaging for unresectable thoracic esophageal cancer.

With respect to simulation, 4D CT may reduce the motion margin [35, 36] and commonly recommend for cervical or lower thoracic esophageal cancer [37–40]. Although 4D CT is available in 89% institutions, 48% ROs still will not use 4D CT in routine simulation for esophageal cancer. With more clinical studies with 4D CT in China [39, 40], it will be more used in the routine simulation in the future. For target contour, X-Ray barium fluoroscopy simulation is commonly used to double check in China. Endoscopic mucosal clips and PET are increasingly applied to define primary esophageal tumor in high-volume hospital in China.

With respect to target volume, our survey indicated that 75% ROs defined CTV margin as the primary tumor plus 3 cm superiorly and inferiorly along the length of the esophagus; this margin was from Gao et al. study in China [41] and consistent with NCCN guideline recommendation [26]. The whole esophagus (RTOG 8501) and 5 cm margin (INT 0123) superiorly and inferiorly along the length of esophagus are seldom used in current clinical practice. For cervical cancer, it’s more controversial for the CTV margin superiorly along the length of the esophagus. Although it’s reasonable that we could use laryngoscopy...
daily imaging guided RT are necessary to be performed widely used to improve RT accuracy. Future goals include better classification of esophageal cancer, standardization of treatment strategy, radiation dose, and target contour, and application of 4D CT and daily imaging guidance, and pursuit of randomized trials in Chinese population.

**MATERIALS AND METHODS**

Five hundred 30-item questionnaires were distributed to Chinese ROs who participated in the first annual meeting of the Chinese Anti-Cancer Association in Jinan, Shandong Province, in August 11–14th, 2016. ROs were first asked details about demographics and clinical experiences, then answered questions pertaining to the clinical management of ESCC with RT. ROs were instructed to select answers closest to their own clinical practice. The questions chiefly covered hot topics on the treatment strategy, RT dose, target delineation, and RT delivery. Supplementary Table 1 showed a complete list of the 30 survey questions. All responses to questions, including partial responses, were deemed eligible for analysis using descriptive statistics.

**Abbreviations**

RT, radiation therapy; ESCC, esophageal squamous cell carcinoma; ROs, radiation oncologists; CRT, chemoradiotherapy; ENI, elective nodal irradiation; INI, involved nodal irradiation; 4D CT, four-dimensional computer tomography; IGRT, image-guided radiotherapy; OS, overall survival; PET, positron emission tomography; GTV, gross tumor volume; CTV, clinical target volume; OAR, organ at risk; 2D, two-dimensional; kV, kilovoltage; EPID, electronic portal imaging device; 3D, three-dimensional; CBCT, cone-beam computer tomography; MV, megavoltage; CCRT, concurrent chemoradiation

**Authors’ contributions**

YZ, JL and JBY designed the study, contributed to the data collection, and drafted the manuscript. YZ and JL contributed to data collection and analysis. WCZ, WYD participated in the analysis of the data described in this paper. All authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

Not applicable.

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.
REFERENCES

1. Tan C, Qian X, Guan Z, Yang B, Ge Y, Wang F, Cai J. Potential biomarkers for esophageal cancer. Springerplus. 2016; 5:467.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7–30. doi: 10.3322/caac.21387.
3. Zuo TT, Zheng RS, Zeng HM, Zhang SW, Chen WQ, He J. Incidence and trend analysis of esophageal cancer in China. Chin J Oncol. 2016; 38:703–708.
4. Zhang SW, Zheng RS, Zuo TT, Zeng HM, Chen WQ, He J. Mortality and survival analysis of esophageal cancer in China. Chin J Oncol. 2016; 38:709–715.
5. Lin SH, Hallemeier CL, Chuong M. Proton beam therapy for the treatment of esophageal cancer. Chin Clin Oncol. 2016; 5:53.
6. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hosiers GA, Bovenkamp JJ, Cuesta MA, Blaise RJ, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16:1090–1098.
7. Ohtsu A. Chemoradiotherapy for esophageal cancer: current status and perspectives. Int J Clin Oncol. 2004; 9:444–450.
8. Noordman BJ, Shapiro J, Spanander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ, SANO study group. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc. 2015; 4:e79.
9. Tai P, Yu E. Esophageal cancer management controversies: Radiation oncology point of view. World J Gastrointest Oncol. 2014; 6:263–274.
10. Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbeck Arch Surg. 2013; 398:177–187.
11. Li M, Zhang X, Zhao F, Lou K, Yu J. Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. Radiat Oncol. 2016; 11:18.
12. Yan H, Tian Z, Shao Y, Jiang SB, Jia X. A new scheme for real-time high-contrast imaging in lung cancer radiotherapy: a proof-of-concept study. Phys Med Biol. 2016; 61:2372–2388.
13. Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, Geh JI, Griffiths EA. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. Ann Surg. 2016; 1.
14. Liu SL, Yang H, Zhang P, Zhang L, Zhao L, Luo LL, Fu JH, Liu MZ, Xi M. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study. Radiother Oncol. 2015; 116:262–268.
15. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of Postoperative Complications After Trimodality Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2013; 86:885–891.
16. Cancer Genome Atlas Research Network, Analysis Working Group, Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, Brown University, Case Western Reserve University, Dana-Farber Cancer Institute, Duke University, Greater Poland Cancer Centre, Harvard Medical School, Institute for Systems Biology, KU Leuven, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541:169–175.
17. Cohen DJ, Leichman L. Controversies in the Treatment of Local and Locally Advanced Gastric and Esophageal Cancers. J Clin Oncol. 2015; 33 33:1754–1759.
18. Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG, Wang LJ. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003; 75:331–336.
19. Yang H, Fu J, Liu M, Chen Y, Chen Z, Zhu C, Yang H, Fang W, Wang J, Yu Z, Pang Q, Mao W, Zhang H, et al. A phase III clinical trial of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus. Ann Oncol. 2016; 27:6110.
20. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17:409–422.
21. Meng X, Wang J, Sun X, Wang L, Ye M, Feng P, Zhu G, Lu Y, Han C, Zhu S, Liao Z, Yu J. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trial. Radiother Oncol. 2013; 109:275–280.
22. Suntharalingam M, Winters K, Ilson D, Dicker AP, Kaehnic LA, Konski AA, Chakravartthy B, Anker CJ, Thakrar H, Horiba N, Kavadi V, Deutsch M, Raben A, et al. The Initial Report of Local Control on RTOG 0416: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Treated Without Surgery. Int J Radiat Oncol Biol Phys. 2013; 90:S3.
23. Brower JV, Chen S, Bassetti MF, Yu M, Harari PM, Ritter MA, Baschnagel AM. Radiation Dose Escalation in Esophageal Cancer Revisited: Contemporary Analysis of the National Cancer Data Base, 2004–2012. Int J Radiat Oncol Biol Phys. 2016; 96:985–993.
24. Streeter OE Jr, Martz KL, Gaspar LE, Delrowe JD, Asbell SO, Salter MM, Roach M 3rd. Does race influence
survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85–01? Int J Radiat Oncol Biol Phys. 1999; 44:1047–1052.

25. Minsky BD, Pajak TF, Ginsberg RJ, Pisanskyy TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20:1167–1174.

26. National Comprehensive Cancer Network (NCCN) Guidelines for Esophageal and Esophagogastric Junction Cancers, version 3.2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed January 15th, 2016.

27. Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, Group EGW. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27:v50–v57.

28. Zhao KL, Shi XH, Jiang GL, Yao WQ, Guo XM, Wu GD, Zhu LX. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study. Int J Radiat Oncol Biol Phys. 2005; 62:1014–1020.

29. Zhao KL, Ma JB, Liu G, Wu KL, Shi XH, Jiang GL. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys. 2010; 76:446–451.

30. Wu SX, Wang LH. Current status and perspectives of radiotherapy for esophageal cancer. Chin J Oncol. 2016; 38:650–654.

31. Yamoah K, Showalter TN, Ohri N. Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys. 2015; 93:737–745.

32. Berger B, Belka C. Evidence-based radiation oncology: oesophagus. Radiother Oncol. 2009; 92:276–290.

33. Chen CY, Li CC, Chien CR. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol. 2016; 120:136–139.

34. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, et al. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. J Thorac Oncol. 2017; 12:375–382.

35. Peng J, Zhang Z, Wang J, Xie J, Hu W. Is internal target volume accurate for dose evaluation in lung cancer stereotactic body radiotherapy? Oncotarget. 2016; 7:22523–22530. doi: 10.18632/oncotarget.8000.

36. Koybasi O, Mishra P, St JS, Lewis JH, Seco J. Simulation of dosimetric consequences of 4D-CT-based motion margin estimation for proton radiotherapy using patient tumor motion data. Phys Med Biol. 2014; 9:853–867.

37. Patel AA, Wollfgang JA, Niemierko A, Hong TS, Yock T, Choi NC. Implications of respiratory motion as measured by four-dimensional computed tomography for radiation treatment planning of esophageal cancer. Int J Radiat Oncol Biol Phys. 2009; 74:290–296.

38. Vlachaki M, Castellon I, Leite C, Perkins T, Ahmad S. Impact of respiratory gating using 4-dimensional computed tomography on the dosimetry of tumor and normal tissues in patients with thoracic malignancies. Am J Clin Oncol. 2009; 32:262–268.

39. Wang JZ, Li JB, Qi HP, Li YK, Wang Y, Zhang YJ, Wang W. Effect of contrast enhancement in delineating GTV and constructing IGTV of thoracic oesophageal cancer based on 4D-CT scans. Radiother Oncol. 2016; 119:172–178.

40. Wang JZ, Li JB, Wang W, Qi ZF, Zhang YJ, Li FX, Fan TY, Shao Q, Xu M. Changes in tumour volume and motion during radiotherapy for thoracic oesophageal cancer. Radiother Oncol. 2015; 114:201–205.

41. Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007; 67:389–396.

42. Wu S, Zhang X, Xia B, Luo H, Li J, Zheng A, Xie C, Wang L, Hu W, Lian X, Du D, Chen M, Bian X, et al. Interim results of a randomized controlled phase III trial of elective nodal irradiation plus erlotinib combined with chemotherapy for esophageal squamous cell carcinoma (NCT00686114). Ann Oncol. 2014; 25:iv211.

43. Jiang L, Zhao X, Meng X, Yu J. Involved field irradiation for the treatment of esophageal cancer: Is it better than elective nodal irradiation? Cancer Lett. 2015; 357:69–74.

44. Li T, Yisikandaer A, Zhang X, Wang X, Ma Y, Chen L, Lu B, Chen H, Yang J, Lv J, Lang J. Involved-Field Irradiation vs Elective Nodal Irradiation for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Comparative Interim Analysis of Clinical Outcomes and Toxicities (NCT01551589, CSWOG 003). Int J Radiat Oncol Biol Phys. 2015; 93:S3–S4.

45. Bujold A, Craig T, Jaffray D, Dawson LA. Image-guided radiotherapy: has it influenced patient outcomes? Semin Radiat Oncol. 2012; 22:50–61.

46. Goyal S, Bodaheggemann J, Wertz H, Loeb I, Rahn A, Walter C, Bodaheggemann J, Wertz H, Loeb I, Rahn A, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2000; 18:1008–9.

47. Mariette C, Robb WB, Piessen G, Adenis A. Neoadjuvant chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol. 2016; 120:136–139.

48. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, et al. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. J Thorac Oncol. 2017; 12:375–382.

49. Peng J, Zhang Z, Wang J, Xie J, Hu W. Is internal target volume accurate for dose evaluation in lung cancer stereotactic body radiotherapy? Oncotarget. 2016; 7:22523–22530. doi: 10.18632/oncotarget.8000.